UnknownEarly Phase 1NCT05085444

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhejiang University
Principal Investigator
He Huang, PhD
First Affiliated Hospital of Zhejiang University
Intervention
Assigned Interventions CD19/BCMA CAR T-cells(biological)
Enrollment
9 enrolled
Eligibility
All sexes
Timeline
20212024

Study locations (1)

Collaborators

Yake Biotechnology Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05085444 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials